Form Approved OMB No. 0920-1385 Exp. Date: 3/31/26

Triazole-resistant Aspergillus fumigatus case report form

Unique patient ID (DCIPHER):		
ARLN specimen ID:	ARLN isolate ID:	ARLN patient ID:
Form completion data		
Name of person completing this f	orm:	
Institution:		
Email:		
Telephone:		
Date form completed:		
Date of incident specimen collecting *This is the earliest date that a pa		
A. Patient demographics		
1. Age at DISC:		
(use months or days if patient	□ Vears □ Mor	nths □ Days □ Unknown
was aged <2 years)		itiis a bays a officiowiff
2.Assigned sex at birth	□ Male □ Female □ Unkn	own
3. Gender identity	☐ Male ☐ Female ☐ Trans☐ Prefer not to answer/Declin	sgender, non-binary, or another gender
4. Ethnic origin		ne □ Unknown Hispanic or Latino □ Unknown
4. Ethnic origin	☐ HISPAINC OF LAUNO	Hispanic of Latino Onknown
5. Race (select all that apply)	□ American Indian/Alaska Na	tive □ Asian □ Black/African American
	□ Native Hawaiian/Pacific Isla	ander 🗆 White 🗆 Unknown
6. Patient's county of residence	<u>.</u>	
(Please do not write the word		□ Unknown
"County"; for example, write		2 Olikiowii
"Cook" instead of "Cook		
County"):		
County 7.		
7. Patient's state, jurisdiction, or		
territory of residence		□ Unknown
8. Patient's country of residence		
(e.g., USA)		□ Unknown
9. Healthcare facility name	<u> </u>	
9. Healthcare facility flame		
(Note: 'healthcare facility' refers		□ Unknown
to the facility where the		- Chillown
patient's incident specimen was		
collected)		
10. Healthcare facility CMS ID #	<u> </u>	
]		□ Unknown

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

A. Patient Demographics (continued)		
11. Healthcare facility ZIP code	□ Unknown	
12. Healthcare facility state, jurisdiction, or territory	□ Unknown	
13. Healthcare facility type	□ Acute care hospital (ACH) □ Long-term acute care hospital (LTACH) □ Skilled nursing facility with ventilated residents (vSNF) □ Skilled nursing facility without ventilated residents (SNF) □ Outpatient □ Unknown □ Other	

B. Detions underlying viel, feetone Consultation and the consultation	and the 2 years hafers DISC (unless ather time from a result of
B. Patient underlying risk factors & medical conditions present during 1. Cancer □ Yes □ No □ Unknown □ Hematologic malignancy specify type: □ □ Solid organ malignancy specify type: □ □ Chemotherapy If yes, specify: □ □ Unknown 1. Cancer □ Yes □ No □ Unknown If yes, choose one of the below Ever had CD4 < 200 cells/mm³ within past 6 months □ Yes □ No □ Unknown	3. Chronic pulmonary diagnosis □ Yes □ No □ Unknown □ Chronic obstructive pulmonary disease (COPD) or emphysema □ Bronchiectasis □ Cystic fibrosis □ Allergic bronchopulmonary aspergillosis (ABPA) □ Pulmonary fibrosis □ Asthma □ Interstitial Lung Disease □ Other chronic pulmonary diagnosis (specify):
4. Positive respiratory viral test in 120 days before or after DISC ☐ Yes ☐ No ☐ Unknown	5. Transplant received within 2 years before DISC □ Yes □ No □ Unknown
If yes, (select all that apply): □ SARS-CoV-2 (PCR or antigen test) □ antigen □ PCR □ unknown test type □ Influenza □ Other respiratory virus (specify)	□ Solid organ transplant: □ Lung □ Heart □ Kidney □ Pancreas □ Liver □ Skin graft □Other:
6. Other selected conditions: ☐ Yes ☐ No ☐ Unknown	☐ Hematopoietic stem cell transplant (HSCT)
Cardiovascular disease So Onknown Cardiovascular disease Specify): Diabetes mellitus End stage renal disease/dialysis Autoimmune disease(s) or inherited immunodeficiency(-ies) (specify): Medications/therapies that weaken the immune system TNF-alpha inhibitors (e.g., infliximab, adalimumab, etanercept) Other (specify):	7. Other potentially relevant clinical information? □ Yes (specify below) □ No □ Unknown
□ Cirrhosis □ Liver disease without cirrhosis □ Systemic lupus erythematosus □ Active tuberculosis □ Pregnant □ Pregnant on DISC Gestational age (weeks): Unknown	

□ Post-partum (gave birth	within 6 weeks before DISC)
---------------------------	-----------------------------

C. Patient diagnosis and outcomes		
1. According to treating clinicians, which	□ Invasive pulmonary aspergillosis (IPA)	
clinical syndrome(s) related to Aspergillus did the patient have?	□ Other disease/syndrome(s) related to A. fumigatus:	
	□ Aspergillus was not believed to be causing clinical illness or is not mentioned in medical records	
	□ Unknown	
2. Was the patient hospitalized at an acute	□ Yes □ No □ Unknown	
care hospital in the 30 days before to 30 days	If yes, dates of admission of hospitalization most proximal to DISC,	
after DISC?	Admission date: (mm-dd-yyyy)	
	min du yyyy	
	Discharge date: (mm-dd-yyyy) □ Still hospitalized	
	If yes,	
	Received ICU-level care in the 14 days <i>before</i> DISC?: ☐ Yes ☐ No ☐ Unknown	
	Received ICU-level care in the 14 days <i>after</i> DISC?: □ Yes □ No □ Unknown	
	Discharge ICD-10 diagnosis code(s):	
3. Died within 30 days after DISC?	□No	
	□ Yes, date of death (mm-dd-yyyy) Cause(s) of death	
	□ Unknown	

Unknowr	ingal treatment: Did the patient receivent in the patient receivent in the table below for each		ays before to 30 days after th	e DISC? □ Yes □ No □
	e of the following to complete each ro			
Amphote Liposoma Amphote	ericin B lipid complex (ABLC) al Amphotericin B (L-AmB) ericin B colloidal dispersion (ABCD) ungin (ANF)	Caspofungin (CAS) I: Fluconazole (Not mold- I: active) (FLC) N Flucytosine (5FC)	traconazole (ITC) Micafungin (MFG)	her drug (specify):
Drug Abbrev	b. First date given (mm-dd-yyyy)	c. Last date given (mm-dd-yyyy)	d. Indication	e. Therapeutic drug monitoring (TDM)
	☐ Start date unknown☐ Start date was >60 days before☐ DISC☐	□ Still on treatment at time CRF completed □ Stop date unknown	□ Prophylaxis □ Treatment for Aspergillus □ Treatment for non- Aspergillus infection	Date of second TDM: TDM level:
		☐ Still on treatment at time CRF completed ☐ Stop date unknown	□ Prophylaxis □ Treatment for Aspergillus □ Treatment for non- Aspergillus infection	□ No □ Yes Date of earliest TDM: TDM level: Date of second TDM: TDM level: □ No
		□ Still on treatment at time CRF completed □ Stop date unknown	□ Prophylaxis □ Treatment for Aspergillus □ Treatment for non- Aspergillus infection	□ Yes Date of earliest TDM: TDM level: Date of second TDM: TDM level: □ No
	☐ Start date unknown☐ Start date was >60 days before☐ DISC☐	 Still on treatment at time CRF completed □ Stop date unknown	☐ Prophylaxis ☐ Treatment for Aspergillus ☐ Treatment for non- Aspergillus infection	☐ Yes Date of earliest TDM: TDM level:
	□ Start date unknown □ Start date was >60 days before DISC		☐ Prophylaxis ☐ Treatment for Aspergillus ☐ Treatment for non- Aspergillus infection	☐ Yes Date of earliest TDM:

Supplemental patient interview form:			
Note that "you" in these question	is refers to the patient.		
1. Person interviewed	☐ Patient ☐ Someone other than the patient, (specify relationship to patient):		
2. What was your job or occupation before [DISC]?	□ Unemployed □ Student □ Retired □ N/A		

	□ Refused to answer □ Unknown			
3. What was your industry	□ Unemployed □ Student □ Retired □ N/A			
before [DISC]?	□ Refused to	o answer □ Unknown		
3. Did you travel outside of [healthcare facility state] within 3 months before [DISC]? (note: if healthcare facility is in a different state from patient's residence, then please count time spent in the patient's home state as "travel") List state(s), territory(-ies), jurisdiction(s), country(-ies)	□ Yes □ No □ Unknown			
4. Did you perform any of the following activities during the 90 days before [DISC]	Gardening Handling compost Handling a fungicide product (agriculture) Handling a fungicide product (home gardening) Spending time on a farm If patient spent time on a farm in 90 days before applicable), and activities performed on farm:			
Additional comments:				